Company intelligence / Profile preview

Bactolife

Copenhagen, Capital Region, Denmarkbactolife.com ↗

Ownership: Private
Employees: ~40
Development stage: Preclinical

Overview

The company has proof of concept of its technology from testing its most advanced animal health product, Ablacto+, which stabilizes the gut of piglets and reduces the severity of post-weaning diarrhea (PWD), in more than 6,000 piglets[5].

Therapeutic areas: Infectious Diseases
Modalities: Binding Proteins
Industry: Biotech

Drug pipeline

1 asset

Ablacto+

Pre-clinical

Indications: Post-weaning diarrhea

Beyond the preview

Go deeper on Bactolife.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bactolife.

Explore the full profile